Mcdonald Partners LLC Sells 3,465 Shares of Amgen Inc. $AMGN

Mcdonald Partners LLC cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 16.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 17,671 shares of the medical research company’s stock after selling 3,465 shares during the quarter. Amgen accounts for approximately 1.5% of Mcdonald Partners LLC’s investment portfolio, making the stock its 14th largest position. Mcdonald Partners LLC’s holdings in Amgen were worth $4,987,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Cresset Asset Management LLC raised its position in shares of Amgen by 0.5% during the 3rd quarter. Cresset Asset Management LLC now owns 51,039 shares of the medical research company’s stock valued at $14,403,000 after buying an additional 269 shares in the last quarter. Level Four Advisory Services LLC grew its position in Amgen by 2.8% in the third quarter. Level Four Advisory Services LLC now owns 14,009 shares of the medical research company’s stock worth $3,953,000 after acquiring an additional 377 shares in the last quarter. Kingsview Wealth Management LLC increased its stake in Amgen by 1.2% during the third quarter. Kingsview Wealth Management LLC now owns 40,732 shares of the medical research company’s stock worth $11,495,000 after acquiring an additional 481 shares during the last quarter. 111 Capital purchased a new stake in Amgen during the third quarter valued at approximately $1,931,000. Finally, Elo Mutual Pension Insurance Co boosted its holdings in shares of Amgen by 2.3% in the 3rd quarter. Elo Mutual Pension Insurance Co now owns 62,898 shares of the medical research company’s stock worth $17,750,000 after purchasing an additional 1,417 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Shares of AMGN stock opened at $377.00 on Wednesday. The company has a market capitalization of $203.23 billion, a P/E ratio of 26.49, a P/E/G ratio of 3.83 and a beta of 0.45. The company’s 50-day simple moving average is $350.89 and its two-hundred day simple moving average is $321.17. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same quarter in the previous year, the business earned $5.31 earnings per share. Amgen’s quarterly revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio is currently 70.84%.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen hit an annual high within a Nasdaq-100 index rally, highlighting strong recent price momentum and renewed investor interest that can support upside if broader tech/healthcare flows continue. Amgen (NASDAQ:AMGN) Hits Annual High Within The Nasdaq 100 Index Rally
• Positive Sentiment: Oppenheimer named AMGN among top momentum stocks, which can attract short-term inflows from momentum- and quant-driven funds. AAPL, AA, BKR, and AMGN are among the top stocks for momentum, says Oppenheimer
• Positive Sentiment: Industry market research points to long-term growth in asthma and biologics markets — an expanding opportunity set for Amgen’s respiratory and biologics franchises if its pipeline and commercialization execute. 7MM Asthma Market Insights, Epidemiology, and Market Forecast Report 2022-2036
• Neutral Sentiment: Amgen presented at the TD Cowen healthcare conference (transcript available) — such presentations can update investors on commercial performance and pipeline timing but typically move stock only when new guidance or surprises appear. Amgen Inc. (AMGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Neutral Sentiment: Coverage pieces from Zacks and Yahoo signal increased retail/institutional attention — visibility that can amplify both rallies and pullbacks depending on order flow. Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Reported short-interest entries in the feed show anomalous “0 shares / NaN” data — this looks like a data error and should not be treated as meaningful evidence of rising short pressure without corroboration from an official short-interest report. (Monitor official short-interest filings for clarity.)
• Negative Sentiment: Sanofi received an orphan-drug designation for Wayrilz in IgG4-related disease in Japan — a regulatory win for a competitor that could create niche competition in specific indications and modestly pressure expectations where overlap exists. Sanofi’s Wayrilz Gets Orphan Drug Tag for IgG4-Related Disease in Japan
• Negative Sentiment: After reaching an annual high, the stock’s pullback looks consistent with profit-taking and sector rotation; that technical unwind can outweigh near-term fundamental positives if macro sentiment turns risk-off.

Analyst Ratings Changes

Several analysts recently weighed in on AMGN shares. Freedom Capital lowered Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 12th. Royal Bank Of Canada increased their target price on shares of Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a research note on Wednesday, February 4th. Morgan Stanley raised their target price on shares of Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 4th. DZ Bank upped their price target on shares of Amgen from $335.00 to $364.00 in a report on Monday, November 10th. Finally, Citigroup raised their price objective on shares of Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Amgen has an average rating of “Moderate Buy” and an average price target of $351.76.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.